<DOC>
	<DOCNO>NCT01463605</DOCNO>
	<brief_summary>For patient unable receive surgery local advance esophageal cancer stage , concurrent chemoradiotherapy recommend . But radiotherapy main strategy old patient chemoradiotherapy intolerance . The whole world focus targeted therapy strong specialty mild toxicity . So combined targeted therapy radiotherapy may novel strategy old patient esophageal cancer . Nimotuzumab EGFR monoclonal antibody . This clinical trial study effect safety Nimotuzumab combine radiotherapy old patient esophageal cancer . All patient receive intensity modulate radiotherapy conventional fraction . Nimotuzumab 200mg give weekly patient radiotherapy .</brief_summary>
	<brief_title>Nimotuzumab Combined With Radiotherapy Older Patients With Esophageal Cancer : Single , Non-control Clinical Trial</brief_title>
	<detailed_description>Study Design Primary Purpose : To evaluate response rate , progression-free survival , overall survival complication . Study Phase : Phase II Intervention Model : Targeted therapy combine radiotherapy Number Arms : One Masking : No Allocation : 30 patient one single group Enrollment : 30 patient Eligibility Criteria Inclusion Criteria : 1 . ≥ 70 year-old , 2 . Thoracic segment esophageal cancer stage II IV ( supraclavicular lymph node metastasis ) , 3 . No previous surgery , radiotherapy chemotherapy cancer allow , 4 . Estimated survival time ≥ 3 month , 5 . KPS &gt; 60 , 6 . No serious disease important organ , 7 . Signed consent form voluntarily . Exclusion Criteria : 1 . Psychopath , 2 . History malignant disease cure , 3 . Joining clinical trial prior study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . ≥ 70 yearold 2 . Thoracic segment esophageal cancer stage II IV ( supraclavicular lymph node metastasis ) 3 . No previous surgery , radiotherapy chemotherapy cancer allow 4 . Estimated survival time ≥ 3 month 5 . KPS &gt; 60 6 . No serious disease important organ 7 . Signed consent form voluntarily 1 . Psychopath 2 . History malignant disease cure 3 . Joining clinical trial prior study .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>target therapy</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>old</keyword>
</DOC>